Clinical trial
A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months
NCT01480258 is registered in ClinicalTrials.gov with MCM Vaccines B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months
- Lead sponsor
- MCM Vaccines B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 23, 2011
- Completion date
- October 9, 2013
- Enrollment
- 1,315 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.